Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Current Deferred Tax Assets (2016 - 2019)

Regen BioPharma (RGBPP) has disclosed Current Deferred Tax Assets for 6 consecutive years, with $4.2 million as the latest value for Q3 2019.

  • On a quarterly basis, Current Deferred Tax Assets rose 14.56% to $4.2 million in Q3 2019 year-over-year; TTM through Sep 2019 was $4.2 million, a 14.56% increase, with the full-year FY2019 number at $4.2 million, up 14.56% from a year prior.
  • Current Deferred Tax Assets was $4.2 million for Q3 2019 at Regen BioPharma, up from $3.6 million in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $7.7 million in Q4 2016 to a low of $3.0 million in Q1 2017.
  • A 5-year average of $4.6 million and a median of $4.2 million in 2019 define the central range for Current Deferred Tax Assets.
  • Peak YoY movement for Current Deferred Tax Assets: skyrocketed 995.32% in 2015, then plummeted 42.5% in 2017.
  • Regen BioPharma's Current Deferred Tax Assets stood at $4.9 million in 2015, then soared by 58.74% to $7.7 million in 2016, then crashed by 31.75% to $5.3 million in 2017, then crashed by 31.87% to $3.6 million in 2018, then rose by 16.76% to $4.2 million in 2019.
  • Per Business Quant, the three most recent readings for RGBPP's Current Deferred Tax Assets are $4.2 million (Q3 2019), $3.6 million (Q4 2018), and $3.7 million (Q3 2018).